Nitric oxide is under clinical development by SaNOtize Research and Development and currently in Phase II for Warts. According to GlobalData, Phase II drugs for Warts have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Nitric oxide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nitric oxide overview
Nitric oxide (FabiSpray) is a free radical which acts as a bronchodilator agent. It is formulated as spray for inhalational route of administation. FabiSpray is indicated for the treatment of adult patients with COVID-19 who have high risk of progression of the disease.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
SaNOtize Research and Development overview
SaNOtize Research and Development (Sanotize) is a biotechnology company focusing on nitric oxide releasing solution platform technology to treat and prevent microbial infections, including drug resistant microbes. Sanotize is headquartered in Vancouver, British Columbia, Canada.
For a complete picture of Nitric oxide’s drug-specific PTSR and LoA scores, buy the report here.